Engineering Drugs for Personalized Medicines

Inventor of Zelboraf^® and Turalio^®

Plexxikon Inc. has closed its office and research facility permanently as of March 31, 2022.

For more information about the closure, please refer to Daiichi Sankyo Company, Ltd.’s press release regarding the closure here.

If you have any additional questions related to the closure or to Plexxikon’s business, please contact one of the following persons listed below:

Amy Klug, Secretary: amy.klug@daiichisankyo.com
Mina Thomas, Assistant Secretary: mina.thomas@daiichisankyo.com
Kenjiro Konishi, Treasurer: Kenjiro.konishi.01@daiichisankyo.com